Business Description
Kalaris Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US4829291065
Total Employee Number:
20Description
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 68.95 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.9 | |||||
3-Year EPS without NRI Growth Rate | 37.7 | |||||
3-Year FCF Growth Rate | 30 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.79 | |||||
9-Day RSI | 60.67 | |||||
14-Day RSI | 53.88 | |||||
3-1 Month Momentum % | -19.69 | |||||
6-1 Month Momentum % | -43.98 | |||||
12-1 Month Momentum % | 81.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.19 | |||||
Quick Ratio | 12.19 | |||||
Cash Ratio | 12.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 | |||||
Shareholder Yield % | 11.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -72 | |||||
ROA % | -43.35 | |||||
ROIC % | -960.65 | |||||
3-Year ROIIC % | -706.82 | |||||
ROC (Joel Greenblatt) % | -2990.37 | |||||
ROCE % | -46.91 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.57 | |||||
Price-to-Tangible-Book | 1.57 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.35 | |||||
EV-to-FCF | -0.37 | |||||
| Price-to-Net-Current-Asset-Value | 1.88 | |||||
| Price-to-Net-Cash | 1.93 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -38.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KLRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kalaris Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.147 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 97.45 | ||
| 14-Day RSI | 53.88 | ||
| 14-Day ATR ($) | 0.357332 | ||
| 20-Day SMA ($) | 4.38 | ||
| 12-1 Month Momentum % | 81.64 | ||
| 52-Week Range ($) | 2.14 - 11.88 | ||
| Shares Outstanding (Mil) | 23.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kalaris Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kalaris Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 56 days | ||
| General meeting for 2025 | 2026-06-03 11:30 | 4.65 (-5.49%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.73 (-5.78%) | ||
| Annual report for 2025 | 2026-03-17 | 8.81 (-1.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 8.81 (-1.67%) | ||
| review of initial Phase 1a data | 2025-12-17 16:30 | 8.66 (+2.49%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 5.07 (+4.66%) | ||
| Guidance call for 2025 | 2025-06-05 15:00 | 3.09 (+3.34%) | ||
| Guidance call for 2025 | 2025-05-27 08:00 | 2.79 (+0.72%) |
Show
Entries
Kalaris Therapeutics Inc Frequently Asked Questions
What is Kalaris Therapeutics Inc(KLRS)'s stock price today?
The current price of KLRS is $4.68. The 52 week high of KLRS is $11.88 and 52 week low is $2.14.
When is next earnings date of Kalaris Therapeutics Inc(KLRS)?
The next earnings date of Kalaris Therapeutics Inc(KLRS) is 2026-08-31 Est..
Does Kalaris Therapeutics Inc(KLRS) pay dividends? If so, how much?
Kalaris Therapeutics Inc(KLRS) does not pay dividend.
Guru Commentaries on NAS:KLRS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Kalaris Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers